Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
M.D. Anderson Cancer Center
Brigham and Women's Hospital
Duke University
Mayo Clinic
Université de Montréal
University of Pittsburgh
University of Toronto
Washington University School of Medicine
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age greater than 18 years
Have two or more GGOs on initial CT imaging
GGOs must be measure ≤3.0 cm and ≥0.6 cm in the greatest dimension
GGOs must be greater than half ground glass
A biopsy is not necessary for inclusion in the trial. Biopsy of a GGO, even with a diagnosis of adenocarcinoma, does not necessarily preclude enrollment in this surveillance protocol. In other words, patients with a diagnosis of adenocarcinoma are still eligible, at the discretion of the clinician and/or investigator, if they meet the above criteria.
You may not be if
Patients who are actively undergoing lung cancer treatment or have a history of lung cancer, except for cases of completely resected pathologic stage IA nonsmall cell lung cancer (NSCLC). Patients with stage IA NSCLC and multiple GGOs can enroll in this active surveillance protocol after complete resection of the NSCLC and confirmation of stage on final pathologic assessment.
The presence of any solid lesion ≥0.6 cm suspicious for malignancy.
Patients who are actively undergoing treatment for other malignancies
Clareo Health | A Registry for Patients With Multifocal Ground Glass Opacities (GGOs)
